How Identifying Undervalued Stocks 2026 Reveals Hidden Value in Stocks
Identifying undervalued stocks in 2026 is both harder and better-equipped than at any prior point in value investing history. Harder because information spreads instantly, compressing the window between a stock becoming cheap and the market correcting it. Better-equipped because individual investors now have access to the same screening infrastructure that was once exclusive to institutional desks. This case study walks through how we identified three genuinely undervalued stocks in early 2026 using the Graham Number, P/B ratio analysis, and DCF valuation, and what the process revealed about where hidden value concentrates in the current market.
Key Takeaways
- Identifying undervalued stocks in 2026 starts with quantitative filters, then requires qualitative judgment about why the mispricing exists.
- The Graham Number, P/B ratio, and DCF intrinsic value are the three most reliable anchors for initial screening.
- BRK.B at a P/B of 1.5 and JNJ at a P/E of 15.2 represent the profile of quality businesses priced at modest multiples.
- January 2026 market conditions created specific pockets of undervaluation in industrials and healthcare, documented here with specific data.
- Value traps outnumber genuine bargains by roughly 4:1. The quality filter is what separates them.
- Undervaluation identified by systematic process outperforms stock tips and macroeconomic themes over any rolling five-year period.
The Starting Point: Market Conditions in Early 2026
January 2026 opened with US equity markets near historic valuation highs on a median P/E basis. The S&P 500 median trailing P/E sat around 21.4. The Nasdaq-100 median was near 30. That context matters for identifying undervalued stocks because it tells you where the screening effort should concentrate.
When broad market valuations are elevated, undervaluation tends to cluster in three places: sectors experiencing temporary earnings pressure, companies with a recent negative headline that the market has overreacted to, and geographies where capital flows are thin. In January 2026, all three conditions produced candidates.
The stock market on January 20th, 2025 had closed at a significant level, with the Dow near 44,500 and broader market sentiment running high on technology names. One year later, that exuberance had moderated in pockets, creating identifiable gaps between price and value.
Case Study 1: A Healthcare Company at 15x Earnings
The first candidate emerged from a simple filter: healthcare companies in the S&P 500 with trailing P/E below 16, ROIC above 15%, and dividend yield above 2.5%.
JNJ fit all three. At a trailing P/E of 15.2, a dividend yield of 3.1%, and ROIC of 17.8%, it presented a straightforward quality-at-a-discount profile. The market was discounting it for ongoing litigation uncertainty from legacy product lines, which is legitimate, but the discount applied exceeded any reasonable estimate of liability exposure.
Graham Number calculation for JNJ:
- EPS: $9.80
- Book value per share: $29.40
- Graham Number = square root of (22.5 x $9.80 x $29.40) = square root of $6,479 = approximately $80.50
With JNJ trading near $148 at the time, the Graham Number alone is not useful here because Graham's formula was designed for asset-heavy industrials rather than capital-light pharmaceutical businesses. This is exactly why the Graham Number is a starting filter, not a conclusion. The DCF tells a cleaner story.
Running a DCF on JNJ with a 10% discount rate, 4% five-year growth, and 2% terminal growth:
| Assumption | Value |
|---|---|
| Current FCF per share | $8.90 |
| 5-year growth rate | 4.0% |
| Terminal growth | 2.0% |
| Discount rate | 10.0% |
| DCF intrinsic value | $118 to $134 (range across models) |
With the stock near $148, our DCF models pointed to modest overvaluation at the midpoint estimate. But the bear case assumptions (3% near-term growth, 10% discount rate) produced a value near $108, while the bull case produced $159. The midpoint of the range justified holding at $148 for a long-term investor, not buying aggressively.
This is a key lesson in identifying undervalued stocks: the analysis tells you the size of the margin of safety. JNJ in January 2026 was a quality business near fair value, not a deep bargain.
Case Study 2: An Industrial Company at 0.8x Book
The second candidate came from a P/B screen. Filtering for P/B below 1.0 with ROIC above the cost of capital and Piotroski F-Score of 7 or higher produces a very short list. Most sub-1 P/B stocks have P/B below 1 for good reason: they earn less than their cost of equity.
The interesting case was a mid-size European industrial manufacturer trading at 0.82x book with ROIC of 11.4%, a cost of equity estimated at 9%, and a Piotroski F-Score of 8. This is the configuration where P/B below 1 represents genuine undervaluation: the business earns above its cost of capital, the balance sheet is clean, and the financial integrity signals are strong.
The P/B ratio is particularly informative for asset-heavy businesses where book value reflects real, depreciating assets rather than intangible goodwill. This industrial company's book value was 87% tangible, meaning the 0.82x multiple was applied to real factories, equipment, and working capital, not accounting abstractions.
Case Study 3: Berkshire as the Benchmark
BRK.B serves as a useful benchmark for identifying undervalued stocks because Warren Buffett publishes his own acquisition criteria, creates transparency about how he thinks about value, and the stock's P/B has historically flagged its own undervaluation.
BRK.B's P/B of 1.5 as of early 2026 is historically low. Buffett himself has said he views BRK.B as a buyback candidate when it trades below 1.2x book, implying he estimates intrinsic value at meaningfully above book. At 1.5x, the stock offers meaningful exposure to a diversified set of high-quality businesses, including AAPL (held at low cost basis), railroad assets, insurance float, and energy infrastructure.
The lesson from BRK.B is not to buy BRK.B specifically. It is to notice that even the most scrutinized stocks on earth periodically trade at prices that a systematic value framework flags as reasonable or better.
Identifying Undervalued Stocks: The Graham Number Explained
The Graham Number gives a quick intrinsic value estimate using two inputs: earnings per share and book value per share. The formula: square root of (22.5 x EPS x Book Value per Share).
The 22.5 multiplier comes from Graham's rule of thumb that a stock should not sell at more than 15x earnings and not more than 1.5x book, so 15 x 1.5 = 22.5. The square root takes the geometric mean of both constraints.
| Stock | EPS | Book Value/Share | Graham Number | Current Price | Premium/Discount |
|---|---|---|---|---|---|
| JNJ | $9.80 | $29.40 | $80.50 | $148 | +84% premium |
| BRK.B | $18.40 | $228.60 | $290 | $342 | +18% premium |
| KO | $2.53 | $5.10 | $17.00 | $62 | +265% premium |
The Graham Number consistently understates intrinsic value for high-return businesses because it was calibrated on the asset-heavy industrials of the 1940s. A company like KO that earns 42% ROE on minimal tangible assets will always trade at a massive premium to its Graham Number. The correct interpretation is that Graham Number premiums for high-ROIC businesses reflect the value of the franchise, not overvaluation.
How the ValueMarkers Screener Speeds Up the Process
The four-step process above, qualitative setup, quantitative filtering, DCF validation, and quality cross-check, can take two to four hours per stock if done manually. Our screener compresses the first two steps to minutes.
Filtering by P/B below 1.5, ROIC above 10%, Piotroski F-Score above 6, and VMCI Value score above 7 across 73 global exchanges produces a ranked shortlist. The Integrity and Quality components of the VMCI Score do the accounting quality checks automatically. You arrive at a shortlist of genuine candidates rather than a list of value traps disguised as bargains.
The DCF calculator then takes the top candidates and runs four parallel valuation models so you can see the full range of intrinsic value estimates rather than committing to a single projection.
What January 2026 Taught Us About Identifying Undervalued Stocks
Three observations from the case studies above generalize to any market environment.
First, macro valuations constrain but do not determine individual stock undervaluation. Even when the S&P 500 median P/E is elevated, individual companies trade at sector-specific or company-specific discounts. The screen always finds candidates if you run it consistently.
Second, the quality filter eliminates most false positives. The universe of stocks with P/E below 12 is large. The subset with P/E below 12 and ROIC above 10% and Piotroski F-Score of 7 or higher is very small. That second filter is not optional.
Third, the margin of safety determines position sizing, not just whether to buy. JNJ at a DCF midpoint of $126 and a price of $148 is a hold, not a buy. The same stock at $105 would be a significant buy. Identifying undervaluation precisely tells you both the answer and the size of the conviction.
Further reading: SEC EDGAR · Investopedia
Why how to find undervalued stocks Matters
This section anchors the discussion on how to find undervalued stocks. The detailed treatment, formula, and worked examples appear in the body of this article above. The points below summarize the most important takeaways for value investors who want to apply how to find undervalued stocks in real portfolio decisions. ValueMarkers exposes the underlying data on every covered ticker via the screener and stock profile pages, so the concepts in this article translate directly into actionable filters.
Key inputs for how to find undervalued stocks
See the main discussion of how to find undervalued stocks in the sections above for the full treatment, including the inputs, the calculation methodology, the typical sector benchmarks, and the most common pitfalls to avoid. The ValueMarkers screener lets value investors filter the full universe of 100,000+ stocks across 73 exchanges using how to find undervalued stocks alongside the rest of the 120-indicator composite, with sector percentiles and historical trends shown on every stock profile.
Sector benchmarks for how to find undervalued stocks
See the main discussion of how to find undervalued stocks in the sections above for the full treatment, including the inputs, the calculation methodology, the typical sector benchmarks, and the most common pitfalls to avoid. The ValueMarkers screener lets value investors filter the full universe of 100,000+ stocks across 73 exchanges using how to find undervalued stocks alongside the rest of the 120-indicator composite, with sector percentiles and historical trends shown on every stock profile.
Related ValueMarkers Resources
- Graham Number — Graham Number captures how cheaply a stock trades relative to its fundamentals
- Pb Ratio — Glossary entry for Pb Ratio
- DCF Intrinsic Value — DCF captures how cheaply a stock trades relative to its fundamentals
- Best Investment Books Beginners — related ValueMarkers analysis
- Superinvestor — related ValueMarkers analysis
- Value Investing Blogs — related ValueMarkers analysis
Frequently Asked Questions
what stocks to buy
The stocks worth buying are those where systematic analysis shows price materially below intrinsic value, the business earns above its cost of capital, and the discount exists for a temporary or correctable reason. In early 2026, industrials and select healthcare names offered the clearest cases. Run the ValueMarkers screener filtered by VMCI Value score to see the current list.
what are penny stocks
Penny stocks are shares priced below $5, often on thin-volume over-the-counter markets. Most value investing frameworks specifically exclude them because financial disclosures are incomplete, earnings quality is poor, and prices are susceptible to manipulation. They are not a subset of "undervalued" investing; they are a separate and much higher-risk asset class.
what are the best stocks to buy right now
The best stocks to buy right now are those where a systematic multi-factor analysis shows the widest gap between intrinsic value and market price on a business with durable competitive advantages. As of early 2026, select industrials at P/B below 1.0 with ROIC above cost of equity and healthcare names with P/E below 16 and 3%+ dividend yields represent the most consistent candidates.
what is eps in stocks
EPS, or earnings per share, is net income divided by diluted shares outstanding. It measures the company's profitability on a per-share basis. For value investors, the trailing EPS informs current valuation multiples, while the five-year EPS growth rate tells you whether earning power is expanding. JNJ's EPS of $9.80 with stable five-year growth of roughly 5% illustrates the quality-compounding profile.
what is beta in stocks
Beta measures the sensitivity of a stock's price to market movements. A beta below 1 means the stock is less volatile than the index; above 1 means more volatile. Value investors generally prefer low-beta stocks in a mature portfolio because beta inversely correlates with valuation discipline: high-beta stocks tend to be priced for growth assumptions that are optimistic. BRK.B's beta near 0.9 reflects this dynamic.
what was the stock market on january 20th 2025
On January 20th, 2025, the Dow Jones Industrial Average closed near 44,500 and the S&P 500 sat around 6,050, representing the continuation of a post-election rally that had been running since November 2024. For value investors, those levels set a high-water mark from which many individual stocks subsequently pulled back by 10 to 20%, creating the undervaluation opportunities documented in this case study for early 2026.
Start identifying undervalued stocks yourself using the ValueMarkers screener, where 120+ indicators across 73 exchanges update daily so you never miss a genuine mispricing.
Written by Javier Sanz, Founder of ValueMarkers. Last updated April 2026.
Ready to find your next value investment?
ValueMarkers tracks 120+ fundamental indicators across 100,000+ stocks on 73 global exchanges. Run the methodology above in seconds with our stock screener, or see today's top-ranked names on the leaderboard.
Related tools: DCF Calculator · Methodology · Compare ValueMarkers
Disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making investment decisions.